News Section | Health
Hypertension drugs may help cut Alzheimer’s risk
May 7 : A new study by boffins at the Wake Forest University School of Medicine has found that some high blood pressure or hypertension drugs may help reduce the risk of developing dementia in older adults.
The drugs that researchers believe are protective are part of a class known as ACE inhibitors – specifically those types that reach the brain and may help reduce the inflammation that might contribute to Alzheimer’s disease.
Kaycee Sink, M.D., M.A.S., lead researcher and an assistant professor of internal medicine – gerontology, said that doctors should think about prescribing these drugs.
“For older adults who are going to take an ACE inhibitor drug for blood pressure control, it makes sense for their doctors to prescribe one that goes into the brain,” said Dr Sink.
As a part of the study the researchers analyzed data from the Cardiovascular Health Study, a long-term study of cardiovascular risk factors that involved 5,888 people over 65 years old from Forsyth County in North Carolina, Sacramento County, Calif., Pittsburgh, Pa., and Washington County, Md. The mean age of participants was 75 years old and most participants (64 percent) were women.
They specifically looked at 1,074 study participants who were free of dementia when they entered the study and who were being treated for high blood pressure. They evaluated whether exposure to ACE inhibitors in general – and to the centrally active versus non-centrally active drugs – was related to dementia and cognitive decline.
Compared to other anti-hypertensive drugs, there was no association between exposure to ACE inhibitors as a class and the risk of dementia. The benefits clearly came from taking the centrally active drugs.
The study found a link between taking centrally active ACE inhibitors and lower rates of mental decline as measured by the Modified Mini-Mental State Exam, a test that evaluates memory, language, abstract reasoning and other cognitive functions.
For each year that participants were exposed to ACE inhibitors that cross the blood brain barrier, the decline in test results was 50 percent lower than the decline in people taking other kinds of high blood pressure pills.
The researchers also found that non-centrally active ACE inhibitors were associated with a trend towards an increased risk of dementia. However, the results were not statistically significant, which means that they could have occurred by chance. Dementia was diagnosed by a panel of physicians after reviewing results of magnetic resonance imaging and other tests.
“These results suggest that there is more to treating blood pressure than achieving a goal of 140/80,” said Dr Sink.
“Which drug you choose for blood pressure control can have broader implications. We know that ACE inhibitors protect against heart failure and kidney failure, and now there is evidence that some of them may also protect against dementia,” she added.
Dr Sink said the effects may be related to reducing inflammation in the brain.
“The hypothesis for how they may slow cognitive decline is that they are decreasing inflammation in the brain, and we know that inflammation is important in the development of Alzheimer’s disease,” she said.
“We need to confirm the results in a study in which people are randomly selected to receive either ACE inhibitors that are centrally active or those that aren’t. Hypertension is a risk factor for dementia, so it’s important to know if the type of drug pressure medication a person takes can cut that risk.”
Some ACE (angiotensin-converting enzyme) inhibitors are known as centrally acting because they can cross the blood brain barrier, a specialized system of tiny blood vessels that protects the brain from harmful substances in the blood stream. Centrally acting drugs include captropril (Capoten), fosinopril (Monopril), lisinopril (Prinivil or Zestri), perindopril (Aceon), ramipril (Altace) and trandolapril (Mavik).
The study was presented on May 5 at the annual meeting of the American Geriatrics Society in Seattle. (ANI)
Disclaimer: Bioscholar is not intended to provide medical advice, diagnosis or treatment. The articles are based on peer reviewed research, and discoveries/products mentioned in the articles may not be approved by the regulatory bodies.